VirtuOx Introduces the World's First Way To Identify Cardiac Arrhythmias From Home Sleep Tests and Overnight Pulse Oximetry Testing
VirtuOx Introduces the World's First Way To Identify Cardiac Arrhythmias From Home Sleep Tests and Overnight Pulse Oximetry Testing
SAN FRANCISCO, Oct. 29, 2020 /PRNewswire-PRWeb/ -- VirtuOx, http://virtuox.net/, a global digital health company announces today, CardioCHECK is saving lives by utilizing artificial intelligence to uncover potential cardiac arrhythmias in the patient's home when patients are ordered other medically necessary diagnostic testing.
The VirtuOx CardioCHECK program reviews more than 40,000 new patients each month who are prescribed home-based diagnostic tests like overnight pulse oximetry (POX) to diagnose hypoxemia and home sleep apnea tests (HSAT) to diagnose obstructive sleep apnea.
Under the strict guidance of medical directors, the VirtuOx case management division contacts the prescribing physician when an at-risk patient is identified by the program. The physician is informed of the risk factors and potential testing that may be medically necessary such as long-term holter, cardiac event monitoring and mobile cardiac telemetry
Kyle Miko, founder and CMO for VirtuOx says, "Research has shown arrhythmias are common with patients who have comorbid conditions like sleep apnea and hypoxemia so now offering additional cardiac testing was a natural progression for VirtuOx."
Lee A. Surkin, MD, a board certified cardiologist, sleep physician and medical director of VirtuOx's cardiac monitoring division shared internal data reviewing the first 146 consecutive mobile cardiac telemetry monitor results indicating an astonishing 57% abnormal rate that reached the threshold of recommending a cardiology consultation.
He states, "What VirtuOx is doing by extracting heart rate data from pulse oximetry studies and home sleep apnea tests has not been done before in this industry and is creating brand new screening tools to identify otherwise asymptomatic patients at risk for severe cardiac arrhythmias."
The abnormal rate seen in the first 146 studies interpreted indicates that we are on track to save many patients from significant cardiac morbidity and likely save lives in the process. This is a game changer in patient care from a cardiac standpoint."
Cardiac arrhythmias affect about 14 million people in the USA (5% of the population). Common disorders include: premature ventricular contractions, premature atrial contractions, atrial fibrillation and atrial flutter. The incidence is highly related to age and the presence of underlying heart disease; the incidence approaches 30% following open heart surgery.
Cardiac arrhythmias signs or symptoms may include shortness of breath, fainting, loss of heart function, breathing, and consciousness that leads to death within minutes unless the person receives emergency medical treatment to restart the heart. So, it's important to figure out when an arrhythmia is serious and merits medical attention.
For more information, visit http://virtuox.net/ or call 877-337-7111.
Media Contact: Kyle Miko • VirtuOx • [email protected] • 877-337-7111 ext. 329
About VirtuOx
VirtuOx, Inc. is a privately held healthcare information technology company that provides diagnostic tools and services that enable a variety of healthcare organizations and professionals diagnose and treat diseases through vertically integrated platforms, products and services.
SOURCE VirtuOx
Share this article